ArticleScientific reports2025
Epidemiological and microbiological characterization of Candidozyma auris (Candida auris) isolates from a tertiary hospital in Cairo, Egypt: an 18-month study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Impact of COVID-19 and earthquake disaster on candidemia in the ICU: mortality and treatment outcomes.BMC infectious diseases · 2026Article
- The emerging pathogen Candida auris: host interactions and disease drivers.Journal of biomedical science · 2026Review
- A Cross-Sectional Study to DetermineBioMed research international · 2026Article
- Research progress on the current status of respiratory pathogen infections and their detection methods.Frontiers in microbiology · 2026Review
- Hospital-acquiredJournal of family & community medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candidozyma auris (formerly Candida auris) has emerged as a significant multidrug-resistant pathogen. Among 140 antifungal-resistant Candida spp. isolates, 120 were identified as C. auris using chromogenic agar, VITEK 2, and MALDI-TOF. Most cases (60%) were males, and 59% were aged ≥ 60 years. Bloodstream infections were predominant (60.8%), followed by respiratory (20.8%), urinary tract (15%), and other sites. Liver transplantation (35.8%) was the most common underlying risk factor, followed by post-COVID-19 (30.8%) and cancer (25%). All isolates exhibited thermotolerance, halotolerance, anaerobic blood hemolysis, and biofilm formation. Significant association was observed between virulence enzymes activity and both specimen source and clinical conditions (P < 0.001), with strong activity linked to blood isolates, liver transplant, post-COVID-19, and lung cancer. Among antifungal agents, voriconazole (MIC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.